Report Detail

Table of Contents

    1 Market Overview of Psychedelic Medicine

    • 1.1 Psychedelic Medicine Market Overview
      • 1.1.1 Psychedelic Medicine Product Scope
      • 1.1.2 Psychedelic Medicine Market Status and Outlook
    • 1.2 Global Psychedelic Medicine Market Size Overview by Region 2016 VS 2021 VS 2027
    • 1.3 Global Psychedelic Medicine Market Size by Region (2016-2027)
    • 1.4 Global Psychedelic Medicine Historic Market Size by Region (2016-2021)
    • 1.5 Global Psychedelic Medicine Market Size Forecast by Region (2022-2027)
    • 1.6 Key Regions, Psychedelic Medicine Market Size (2016-2027)
      • 1.6.1 North America Psychedelic Medicine Market Size (2016-2027)
      • 1.6.2 Europe Psychedelic Medicine Market Size (2016-2027)
      • 1.6.3 Asia-Pacific Psychedelic Medicine Market Size (2016-2027)
      • 1.6.4 Latin America Psychedelic Medicine Market Size (2016-2027)
      • 1.6.5 Middle East & Africa Psychedelic Medicine Market Size (2016-2027)

    2 Psychedelic Medicine Market Overview by Type

    • 2.1 Global Psychedelic Medicine Market Size by Type: 2016 VS 2021 VS 2027
    • 2.2 Global Psychedelic Medicine Historic Market Size by Type (2016-2021)
    • 2.3 Global Psychedelic Medicine Forecasted Market Size by Type (2022-2027)
    • 2.4 Psilocybin
    • 2.5 LSD
    • 2.6 MDMA
    • 2.7 DMT
    • 2.8 Ketamine
    • 2.9 Others

    3 Psychedelic Medicine Market Overview by Application

    • 3.1 Global Psychedelic Medicine Market Size by Application: 2016 VS 2021 VS 2027
    • 3.2 Global Psychedelic Medicine Historic Market Size by Application (2016-2021)
    • 3.3 Global Psychedelic Medicine Forecasted Market Size by Application (2022-2027)
    • 3.4 Depressive Disorders
    • 3.5 Post-Traumatic Stress Disorders
    • 3.6 Substance Abuse Disorders
    • 3.7 Obsessive Compulsive Disorders
    • 3.8 Others

    4 Psychedelic Medicine Competition Analysis by Players

    • 4.1 Global Psychedelic Medicine Market Size by Players (2016-2021)
    • 4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Psychedelic Medicine as of 2020)
    • 4.3 Date of Key Players Enter into Psychedelic Medicine Market
    • 4.4 Global Top Players Psychedelic Medicine Headquarters and Area Served
    • 4.5 Key Players Psychedelic Medicine Product Solution and Service
    • 4.6 Competitive Status
      • 4.6.1 Psychedelic Medicine Market Concentration Rate
      • 4.6.2 Mergers & Acquisitions, Expansion Plans

    5 Company (Top Players) Profiles and Key Data

    • 5.1 COMPASS Pathways PLC
      • 5.1.1 COMPASS Pathways PLC Profile
      • 5.1.2 COMPASS Pathways PLC Main Business
      • 5.1.3 COMPASS Pathways PLC Psychedelic Medicine Products, Services and Solutions
      • 5.1.4 COMPASS Pathways PLC Psychedelic Medicine Revenue (US$ Million) & (2016-2021)
      • 5.1.5 COMPASS Pathways PLC Recent Developments
    • 5.2 Pfizer
      • 5.2.1 Pfizer Profile
      • 5.2.2 Pfizer Main Business
      • 5.2.3 Pfizer Psychedelic Medicine Products, Services and Solutions
      • 5.2.4 Pfizer Psychedelic Medicine Revenue (US$ Million) & (2016-2021)
      • 5.2.5 Pfizer Recent Developments
    • 5.3 Eli Lilly
      • 5.3.1 Eli Lilly Profile
      • 5.3.2 Eli Lilly Main Business
      • 5.3.3 Eli Lilly Psychedelic Medicine Products, Services and Solutions
      • 5.3.4 Eli Lilly Psychedelic Medicine Revenue (US$ Million) & (2016-2021)
      • 5.3.5 GlaxoSmithKline Recent Developments
    • 5.4 GlaxoSmithKline
      • 5.4.1 GlaxoSmithKline Profile
      • 5.4.2 GlaxoSmithKline Main Business
      • 5.4.3 GlaxoSmithKline Psychedelic Medicine Products, Services and Solutions
      • 5.4.4 GlaxoSmithKline Psychedelic Medicine Revenue (US$ Million) & (2016-2021)
      • 5.4.5 GlaxoSmithKline Recent Developments
    • 5.5 Cybin Inc
      • 5.5.1 Cybin Inc Profile
      • 5.5.2 Cybin Inc Main Business
      • 5.5.3 Cybin Inc Psychedelic Medicine Products, Services and Solutions
      • 5.5.4 Cybin Inc Psychedelic Medicine Revenue (US$ Million) & (2016-2021)
      • 5.5.5 Cybin Inc Recent Developments
    • 5.6 Field Trip Health
      • 5.6.1 Field Trip Health Profile
      • 5.6.2 Field Trip Health Main Business
      • 5.6.3 Field Trip Health Psychedelic Medicine Products, Services and Solutions
      • 5.6.4 Field Trip Health Psychedelic Medicine Revenue (US$ Million) & (2016-2021)
      • 5.6.5 Field Trip Health Recent Developments
    • 5.7 ATAI Life Sciences
      • 5.7.1 ATAI Life Sciences Profile
      • 5.7.2 ATAI Life Sciences Main Business
      • 5.7.3 ATAI Life Sciences Psychedelic Medicine Products, Services and Solutions
      • 5.7.4 ATAI Life Sciences Psychedelic Medicine Revenue (US$ Million) & (2016-2021)
      • 5.7.5 ATAI Life Sciences Recent Developments
    • 5.8 NUMINUS WELLNESS
      • 5.8.1 NUMINUS WELLNESS Profile
      • 5.8.2 NUMINUS WELLNESS Main Business
      • 5.8.3 NUMINUS WELLNESS Psychedelic Medicine Products, Services and Solutions
      • 5.8.4 NUMINUS WELLNESS Psychedelic Medicine Revenue (US$ Million) & (2016-2021)
      • 5.8.5 NUMINUS WELLNESS Recent Developments
    • 5.9 MindMed
      • 5.9.1 MindMed Profile
      • 5.9.2 MindMed Main Business
      • 5.9.3 MindMed Psychedelic Medicine Products, Services and Solutions
      • 5.9.4 MindMed Psychedelic Medicine Revenue (US$ Million) & (2016-2021)
      • 5.9.5 MindMed Recent Developments
    • 5.10 HAVN Life Sciences
      • 5.10.1 HAVN Life Sciences Profile
      • 5.10.2 HAVN Life Sciences Main Business
      • 5.10.3 HAVN Life Sciences Psychedelic Medicine Products, Services and Solutions
      • 5.10.4 HAVN Life Sciences Psychedelic Medicine Revenue (US$ Million) & (2016-2021)
      • 5.10.5 HAVN Life Sciences Recent Developments
    • 5.11 Seelos Therapeutics
      • 5.11.1 Seelos Therapeutics Profile
      • 5.11.2 Seelos Therapeutics Main Business
      • 5.11.3 Seelos Therapeutics Psychedelic Medicine Products, Services and Solutions
      • 5.11.4 Seelos Therapeutics Psychedelic Medicine Revenue (US$ Million) & (2016-2021)
      • 5.11.5 Seelos Therapeutics Recent Developments
    • 5.12 Jannsen
      • 5.12.1 Jannsen Profile
      • 5.12.2 Jannsen Main Business
      • 5.12.3 Jannsen Psychedelic Medicine Products, Services and Solutions
      • 5.12.4 Jannsen Psychedelic Medicine Revenue (US$ Million) & (2016-2021)
      • 5.12.5 Jannsen Recent Developments
    • 5.13 Acadia Pharmaceuticals
      • 5.13.1 Acadia Pharmaceuticals Profile
      • 5.13.2 Acadia Pharmaceuticals Main Business
      • 5.13.3 Acadia Pharmaceuticals Psychedelic Medicine Products, Services and Solutions
      • 5.13.4 Acadia Pharmaceuticals Psychedelic Medicine Revenue (US$ Million) & (2016-2021)
      • 5.13.5 Acadia Pharmaceuticals Recent Developments
    • 5.14 Intellipharmaceutics
      • 5.14.1 Intellipharmaceutics Profile
      • 5.14.2 Intellipharmaceutics Main Business
      • 5.14.3 Intellipharmaceutics Psychedelic Medicine Products, Services and Solutions
      • 5.14.4 Intellipharmaceutics Psychedelic Medicine Revenue (US$ Million) & (2016-2021)
      • 5.14.5 Intellipharmaceutics Recent Developments
    • 5.15 Revive Therapeutics
      • 5.15.1 Revive Therapeutics Profile
      • 5.15.2 Revive Therapeutics Main Business
      • 5.15.3 Revive Therapeutics Psychedelic Medicine Products, Services and Solutions
      • 5.15.4 Revive Therapeutics Psychedelic Medicine Revenue (US$ Million) & (2016-2021)
      • 5.15.5 Revive Therapeutics Recent Developments
    • 5.16 Mydecine Innovations Group
      • 5.16.1 Mydecine Innovations Group Profile
      • 5.16.2 Mydecine Innovations Group Main Business
      • 5.16.3 Mydecine Innovations Group Psychedelic Medicine Products, Services and Solutions
      • 5.16.4 Mydecine Innovations Group Psychedelic Medicine Revenue (US$ Million) & (2016-2021)
      • 5.16.5 Mydecine Innovations Group Recent Developments
    • 5.17 Red Light Holland
      • 5.17.1 Red Light Holland Profile
      • 5.17.2 Red Light Holland Main Business
      • 5.17.3 Red Light Holland Psychedelic Medicine Products, Services and Solutions
      • 5.17.4 Red Light Holland Psychedelic Medicine Revenue (US$ Million) & (2016-2021)
      • 5.17.5 Red Light Holland Recent Developments
    • 5.18 Braxia Scientific
      • 5.18.1 Braxia Scientific Profile
      • 5.18.2 Braxia Scientific Main Business
      • 5.18.3 Braxia Scientific Psychedelic Medicine Products, Services and Solutions
      • 5.18.4 Braxia Scientific Psychedelic Medicine Revenue (US$ Million) & (2016-2021)
      • 5.18.5 Braxia Scientific Recent Developments
    • 5.19 Mind Cure Health
      • 5.19.1 Mind Cure Health Profile
      • 5.19.2 Mind Cure Health Main Business
      • 5.19.3 Mind Cure Health Psychedelic Medicine Products, Services and Solutions
      • 5.19.4 Mind Cure Health Psychedelic Medicine Revenue (US$ Million) & (2016-2021)
      • 5.19.5 Mind Cure Health Recent Developments
    • 5.20 Entheon Biomedical
      • 5.20.1 Entheon Biomedical Profile
      • 5.20.2 Entheon Biomedical Main Business
      • 5.20.3 Entheon Biomedical Psychedelic Medicine Products, Services and Solutions
      • 5.20.4 Entheon Biomedical Psychedelic Medicine Revenue (US$ Million) & (2016-2021)
      • 5.20.5 Entheon Biomedical Recent Developments

    6 North America

    • 6.1 North America Psychedelic Medicine Market Size by Country (2016-2027)
    • 6.2 United States
    • 6.3 Canada

    7 Europe

    • 7.1 Europe Psychedelic Medicine Market Size by Country (2016-2027)
    • 7.2 Germany
    • 7.3 France
    • 7.4 U.K.
    • 7.5 Italy
    • 7.6 Russia
    • 7.7 Nordic
    • 7.8 Rest of Europe

    8 Asia-Pacific

    • 8.1 Asia-Pacific Psychedelic Medicine Market Size by Region (2016-2027)
    • 8.2 China
    • 8.3 Japan
    • 8.4 South Korea
    • 8.5 Southeast Asia
    • 8.6 India
    • 8.7 Australia
    • 8.8 Rest of Asia-Pacific

    9 Latin America

    • 9.1 Latin America Psychedelic Medicine Market Size by Country (2016-2027)
    • 9.2 Mexico
    • 9.3 Brazil
    • 9.4 Rest of Latin America

    10 Middle East & Africa

    • 10.1 Middle East & Africa Psychedelic Medicine Market Size by Country (2016-2027)
    • 10.2 Turkey
    • 10.3 Saudi Arabia
    • 10.4 UAE
    • 10.5 Rest of Middle East & Africa

    11 Psychedelic Medicine Market Dynamics

    • 11.1 Psychedelic Medicine Industry Trends
    • 11.2 Psychedelic Medicine Market Drivers
    • 11.3 Psychedelic Medicine Market Challenges
    • 11.4 Psychedelic Medicine Market Restraints

    12 Research Finding /Conclusion

      13 Methodology and Data Source

      • 13.1 Methodology/Research Approach
        • 13.1.1 Research Programs/Design
        • 13.1.2 Market Size Estimation
        • 13.1.3 Market Breakdown and Data Triangulation
      • 13.2 Data Source
        • 13.2.1 Secondary Sources
        • 13.2.2 Primary Sources
      • 13.3 Disclaimer

      Market Insights
      QY Research has lately published a report titled “Global Psychedelic Medicine Market Report, History and Forecast 2016-2027, Breakdown Data by Companies, Key Regions, Types and Application”, with the help of industry-leading research methods, along with observing subtle details and understanding the overall dynamics.
      The insights included in this report have been prepared in view of varied aspects that affect the growth. The report elucidates key drivers, trends, prospects, restraining factors, and challenges that players may across in the coming years. With the assistance of this research, players can recognize and capitalize on profitable opportunities. They can further utilize it to make the required advancements in their operations to acquire a competitive advantage over other participants.
      The global Psychedelic Medicine market size is projected to reach US$ million by 2027, from US$ million in 2020, at a CAGR of % during 2021-2027.
      Segment Scope
      An intensive study of key type and application segments has been done in this segmentation section. The authors of the report have provided reliable figures including revenue forecast data by type and application for the period 2016-2027. They have also studied how the segments are gaining or losing growth in various geographies and their respective countries. Thanks to this study, readers can thoroughly grasp the growth pattern and potential of different segments.
      Segment by Type
      Psilocybin
      LSD
      MDMA
      DMT
      Ketamine
      Others
      Segment by Application
      Depressive Disorders
      Post-Traumatic Stress Disorders
      Substance Abuse Disorders
      Obsessive Compulsive Disorders
      Others

      Regional Scope
      This segment of the report offers a thorough regional study of the global Psychedelic Medicine market. Drivers and restraints for each region are broadly examined in the report. Readers will get familiar with the driving forces and challenges that are specific to the regions. The specialists have identified growth opportunities in key geographical regions and their respective countries to aid players to reinforce their presence. All the regions and their countries in the report are assessed based on the growth rate and revenue according to the consumption for the period 2016-2027. This geographical analysis will help readers to gain in-depth knowledge of the regional growth. The key geographical regions surveyed in this research report involve North America, Europe, Asia Pacific, Central and South America, and Middle East and Africa. The report has specifically covered major countries including United States, Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, China Taiwan, Indonesia, Thailand, Malaysia, Mexico, Brazil, Turkey, Saudi Arabia, UAE, etc.

      Key Players
      This section has provided an exhaustive analysis of the strategies that the companies are focusing on to stay ahead of other players. The strategies mainly involve research and development, new product developments, and mergers and acquisitions. The researchers have also provided revenue shares of the key companies, company overview, and the latest company developments so as to help players to sustain the cutthroat competition. In this section, the report offers global revenue data of manufacturers for the period 2016-2021. Following is the list of key manufacturers observed in this research study:
      COMPASS Pathways PLC
      Pfizer
      Eli Lilly
      GlaxoSmithKline
      Cybin Inc
      Field Trip Health
      ATAI Life Sciences
      NUMINUS WELLNESS
      MindMed
      HAVN Life Sciences
      Seelos Therapeutics
      Jannsen
      Acadia Pharmaceuticals
      Intellipharmaceutics
      Revive Therapeutics
      Mydecine Innovations Group
      Red Light Holland
      Braxia Scientific
      Mind Cure Health
      Entheon Biomedical

      Frequently Asked Questions
      Which application segment captured the leading share in the Psychedelic Medicine market?
      How fragmented is the Psychedelic Medicine market?
      Which are the key growth drivers in the Psychedelic Medicine market?
      Which are the top strategies undertaken by the Psychedelic Medicine market players?
      Which technological trends are likely to affect the Psychedelic Medicine market?
      What is the expected Psychedelic Medicine market size by 2027?
      Which companies are dominating the Psychedelic Medicine market?
      Which region is projected to witness the fastest growth in the future?
      What factors are restraining the Psychedelic Medicine market growth?
      Which are the emerging companies in the Psychedelic Medicine market?


      Summary:
      Get latest Market Research Reports on Psychedelic Medicine. Industry analysis & Market Report on Psychedelic Medicine is a syndicated market report, published as Global Psychedelic Medicine Market Report, History and Forecast 2016-2027, Breakdown Data by Companies, Key Regions, Types and Application. It is complete Research Study and Industry Analysis of Psychedelic Medicine market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.

      Last updated on

      REPORT YOU MIGHT BE INTERESTED

      Purchase this Report

      $3,500.00
      $7,000.00
      2,621.50
      5,243.00
      3,111.50
      6,223.00
      403,515.00
      807,030.00
      261,695.00
      523,390.00
      Credit card Logo

      Related Reports


      Reason to Buy

      Request for Sample of this report